Nanosphere Health SciencesNSHSF Piotroski F-Score is 4 as of Jun. 29, 2026, which is at its 10-year median of 4.00. Among 1,339 Biotechnology companies, Nanosphere Health Sciences ranks better than 74.16% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Nanosphere Health Sciences has an F-score of 4 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for Nanosphere Health Sciences's Piotroski F-Score or its related term are showing as below:
NSHSF'
s Piotroski F-Score Range Over the Past 10 Years
Min: 2 Med: 4 Max: 5
Current: 4
During the past 13 years, the highest Piotroski F-Score of Nanosphere Health Sciences was 5. The lowest was 2. And the median was 4.
Nanosphere Health Sciences (OTCPK:NSHSF) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Nanosphere Health Sciences Piotroski F-Score Related Terms
Nanosphere Health Sciences Piotroski F-Score Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanosphere Health Sciences Piotroski F-Score Chart
NSHSF vs VRTX, REGN, ALNY: Piotroski F-Score Comparison
For the Biotechnology subindustry, Nanosphere Health Sciences's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanosphere Health Sciences Piotroski F-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nanosphere Health Sciences's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Nanosphere Health Sciences's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Nanosphere Health Sciences's current Net Income (TTM) was -0.08.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Nanosphere Health Sciences's current Cash Flow from Operations (TTM) was -0.02.
==> Negative ==> Score 0.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
Nanosphere Health Sciences's return on assets of this year was -6. Nanosphere Health Sciences's return on assets of last year was 14.61111111.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Nanosphere Health Sciences's gearing of this year was 0. Nanosphere Health Sciences's gearing of last year was 0.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Nanosphere Health Sciences's current ratio of this year was 0.0124269. Nanosphere Health Sciences's current ratio of last year was 0.01137287.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Nanosphere Health Sciences's number of shares in issue this year was 10.275. Nanosphere Health Sciences's number of shares in issue last year was 10.275.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Nanosphere Health Sciences's gross margin of this year was . Nanosphere Health Sciences's gross margin of last year was .
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Nanosphere Health Sciences's asset turnover of this year was 0. Nanosphere Health Sciences's asset turnover of last year was 0.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
0
+
0
+
1
+
1
+
1
+
1
+
0
+
0
=
4
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Nanosphere Health Sciences has an F-score of 4 indicating the company's financial situation is typical for a stable company.
Nanosphere Health Sciences (NSHSF) has a Piotroski F-Score of 4 as of Jun. 29, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Nanosphere Health Sciences and its competitors. This is near median its historical median of 4.00. Over the past decade, Nanosphere Health Sciences' Piotroski F-Score has ranged from 2.00 to 5.00. According to the industry distribution chart, Nanosphere Health Sciences ranks #346 out of 1339 companies in the Biotechnology industry, placing it in the top 25.8%.
Is Nanosphere Health Sciences' Piotroski F-Score too high?
Nanosphere Health Sciences' current Piotroski F-Score of 4 is near median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 5.00. The Biotechnology industry median Piotroski F-Score is 3.00. Nanosphere Health Sciences' value of 4 is 33.3% above this industry median. Based on the distribution chart, Nanosphere Health Sciences ranks #346 out of 1339 companies in the Biotechnology industry, which is above the industry midpoint.
How does Nanosphere Health Sciences' Piotroski F-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nanosphere Health Sciences ranks #346 out of 1339 companies for Piotroski F-Score. This puts Nanosphere Health Sciences in the upper half of its industry. The industry median Piotroski F-Score is 3.00. Nanosphere Health Sciences' value of 4 is 33.3% above this benchmark. Historically, Nanosphere Health Sciences' own Piotroski F-Score has ranged from 2.00 to 5.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 3.00, Nanosphere Health Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,339 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nanosphere Health Sciences's current Piotroski F-Score of 4 is 33.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Nanosphere Health Sciences and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanosphere Health Sciences's current Piotroski F-Score is 4, which is near median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanosphere Health Sciences stock overvalued right now?
Nanosphere Health Sciences (NSHSF) has a current Piotroski F-Score of 4. The current Piotroski F-Score is 4, which is near median its 10-year median of 4.00 and 33.3% above the Biotechnology industry median of 3.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Nanosphere Health Sciences (NSHSF), the current Piotroski F-Score is 4 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nanosphere Health Sciences Inc is a biotechnology company focused on providing next generation delivery of biologically active compounds through licensing and joint venture arrangements. The Company has developed and is commercializing its patented NanoSphere Delivery System, a nanotechnology platform for the delivery of biological agents such as cannabinoids, supplements, nutraceuticals, and over-the-counter medications for the cannabis, pharmaceutical, and animal health industries. The NanoSphere Delivery System provides improved bioavailability, efficacy, and onset of effect over traditional delivery systems.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSHSF has been successfully added to your 